Fusafungine
![]() | |
Clinical data | |
---|---|
Other names | Fusafungin |
AHFS/Drugs | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
DrugBank | |
UNII | |
KEGG | |
CompTox Dashboard(EPA) | |
ECHA InfoCard | 100.014.306 |
Chemical and physical data | |
Formula | C33H57N3O9 |
Molar mass | 639.831g·mol−1 |
3D model (JSmol) | |
Melting point | 125 to 129 °C (257 to 264 °F) |
| |
![]() ![]() |
Fusafungine(INN), also known asfusafungin,is an active agent used inantibioticsfor treatment ofnasalandthroat infection.It also possessesanti-inflammatoryproperties. Fusafungine is a mixture ofenniatincyclohexadepsipeptidesmade up of alternatingD-α-hydroxyvaleric acid andL-N-methylamino acid residues,[1]produced by theascomyceteFusarium lateritium,and marketed byServierunder the trade namesLocabiotal,Bioparox,andLocabiosol.
According to a pooled analysis study done in the UK for the efficacy of fusafungine inrhinopharingitis,it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.[2]
In February 2016, theEuropean Medicines Agencyrecommended the withdrawal of fusafungine from the market due to rare but severe allergic reactions (mainlybronchospasms).[3]
References
[edit]- ^Levy D, Bluzat A, Seigneuret M, Rigaud JL (December 1995). "Alkali cation transport through liposomes by the antimicrobial fusafungine and its constitutive enniatins".Biochemical Pharmacology.50(12): 2105–7.doi:10.1016/0006-2952(95)02045-4.PMID8849339.
- ^Lund VJ, Grouin JM, Eccles R, Bouter C, Chabolle F (December 2004). "Efficacy of fusafungine in acute rhinopharyngitis: a pooled analysis".Rhinology.42(4): 207–12.PMID15626253.
- ^"CMDh endorses revocation of authorisations for fusafungine sprays used to treat airway infections".European Medicines Agency. 17 September 2018. Archived fromthe originalon 20 June 2018.Retrieved18 February2022.